![](/img/cover-not-exists.png)
B01*A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back
Reni, M., Zanon, S., Balzano, G., Passoni, P., Costantino, A., Pircher, C., Chiaravalli, M., Nicoletti, R., Arcidiacono, P.G., Pepe, G., Crippa, S., Doglioni, C., Fugazza, C., Ceraulo, D., Falconi, M.Volume:
27
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw333.01
Date:
September, 2016
File:
PDF, 69 KB
2016